Profusa Integrates NVIDIA's Advanced Stack to Launch AI-Powered Clinical Intelligence Platform for Real-Time Biomarker Tracking

The intersection of continuous health monitoring and artificial intelligence is reshaping how clinicians access patient data. Profusa, a digital health innovator focused on tissue-integrated sensors, is advancing this frontier by leveraging NVIDIA’s NeMo technology stack to develop a physician-centric intelligence portal designed for real-time biochemistry insights.

The Missing Data Layer in Healthcare AI

Current healthcare systems lack longitudinal, real-time biochemistry datasets at scale—a gap that limits AI’s potential to drive meaningful clinical outcomes. “Real-time biochemistry information across large patient populations represents untapped potential for AI-enabled healthcare breakthroughs,” explains the company’s leadership. Profusa’s position as a provider of continuous biomarker data uniquely positions it to bridge this gap, connecting therapeutic interventions with observable biochemistry changes to surface actionable clinical intelligence previously unavailable to practitioners.

Building the Technology Backbone

By merging Profusa’s Lumee optical monitoring platform with NVIDIA’s industry-standard NeMo hardware and software ecosystem, the company is constructing a scalable infrastructure capable of several key functions:

Intelligent Clinical Workflows: The portal will feature an LLM-powered assistant that integrates seamlessly with electronic medical records (EMR), wearable devices, and home monitoring systems. This agent supports clinical documentation, order management, care planning, remote physiologic monitoring (RPM), remote therapeutic monitoring (RTM), patient triage, and alert escalation.

Continuous Quality Oversight: Built-in experimentation frameworks and performance metrics enable ongoing evaluation of assistant accuracy, data drift detection, and safety validation throughout the system’s lifecycle.

Compliance-First Architecture: Policy-aware orchestration enforces clinical scope boundaries, protects patient privacy, and ensures safe responses across all patient and provider touchpoints.

Adaptive Model Refinement: The platform supports parameter-efficient fine-tuning and post-training optimization of Profusa’s AI signal processing and clinical reasoning capabilities, allowing continuous improvement.

Unified Health Data Context: A longitudinal data graph fuses Profusa biomarkers with EMR records (diagnoses, medications, laboratory results, vital signs, imaging, clinical notes), insurance claims, pharmacy data, wearables and IoT sensors, genomic information, and social determinants of health to power predictive analytics and patient coaching.

From Raw Signals to Actionable Insights

Rather than overwhelming clinicians with additional dashboard complexity, the portal transforms optical sensor signals into trustworthy, always-available clinical intelligence. The system translates raw data into reliable biometrics and contextual clinical guidance, enabling more informed decision-making without increasing information overload.

Timeline and Geographic Rollout

Profusa plans to introduce the physician portal across the European Economic Area (comprising EU member states, Liechtenstein, Norway, and Iceland) during early 2026, following CE Mark certification. The portal will work in conjunction with Profusa’s Lumee injectable hydrogel sensors and associated reader hardware, extending AI-enhanced clinical tools from office-based settings into remote patient monitoring environments.

This development represents a significant step forward in translating continuous biochemical data into clinically actionable intelligence, potentially reshaping how practitioners monitor and manage patient health in real time.

About Profusa: Founded in Berkeley, California, Profusa develops tissue-integrated biosensors that enable continuous, medical-grade data transmission for both personal health tracking and clinical applications. The company’s long-lasting, injectable, and cost-effective biosensor technology combined with its intelligent data platform aims to deliver personalized biochemical profiles that clinicians can confidently utilize for patient care decisions.